15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English AASLD2018[458C]阿德福韦或替诺福韦相互增强 LPS刺激的 ...
查看: 467|回复: 1
go

AASLD2018[458C]阿德福韦或替诺福韦相互增强 LPS刺激的促炎性细 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2018-10-23 15:28 |只看该作者 |倒序浏览 |打印
s 458C
Adefovir or Tenofovir Reciprocally Augments
Pro-Inflammatory Cytokines in LPS-Stimulated
PBMC By Inhibiting IL-10 Production in
CD14+monocytes
Kazumoto Murata, Gastroenterology, International University
of Health and Welfare; Genome Medical Sciences Project,
National Center for Global Health and Medicine, Masaya
Sugiyama, Genome Medical Science Project, National Center
for Global Health and Medicine and Masashi Mizokami,
National Center for Global Health and Medicine
Background: Nucleos(t)ide analogues (NUC) can control
hepatitis B virus (HBV) by inhibiting its reverse transcriptase,
but life-long therapies are generally required. We recently
discovered that adefovir (ADV) or tenofovir (TDF) has
an additional pharmacological anti-HBV effect to induce
IFN-l3 in the gastrointestinal (GI) tracts. Since enteric
lipopolysaccharide (LPS) can cross the intestine and spread
into portal vein, we hypothesized that orally administered
NUC could influence LPS-induced cytokine production in
peripheral blood mononuclear cells (PBMC). Methods:
Whole PBMC or various cells (CD3, CD14, CD19, or CD56)-
depleted PBMC obtained from healthy volunteers (HV) were
incubated with NUC (lamivudine; LAM, ADV, entecavir; ETV,
TDF) or negative control (DMSO), following stimulation with
LPS, with or without IFN-a. PBMC from patients with chronic
HBV infection (asymptomatic carriers (AC); n=8, chronic
hepatitis (CH); n=10, liver cirrhosis (LC); n=5) were also used.
Each cytokine level in the supernatant was measured by Bio-
Plex cytokine assay or enzyme-linked immunosorbent assay
(ELISA). In some experiments, antibodies or recombinant
proteins of interleukin (IL)-10, IL-12p70, or tumor necrosis
factor (TNF)-α were used when PBMC were stimulated
with NUC. Results: Bio-Plex cytokine assay revealed that
ADV or TDF significantly induced IL-12p70 and TNF-α,
and inhibited IL-10, compared with DMSO, LAM, and ETV.
These patterns were similarly observed in PBMC from all 3
HV, which were confirmed by ELISA using PBMC from other
HV. No other cytokines were shown to be significant. ADV or
TDF modulated those cytokine levels in a dose-dependent
manner, which was completely abrogated by depletion of
CD14+monocytes. Comparable results were obtained using
PBMC from HBV patients although all cytokine levels were
significantly lower in patients with LC, compared with HV, AC
or CH. Monoclonal antibody and recombinant protein of IL-
10 significantly enhanced and inhibited IL-12p70 or TNF-α,
respectively, in a dose-dependent manner. In contrast, none
of monoclonal antibodies or recombinant proteins of IL-
12p70 and TNF-α changed IL-10 levels regardless of their
concentration used. Collectively, ADV or TDF initially inhibits
LPS-mediated IL-10 production and reciprocally induced IL-
12p70 and TNF-α. In addition, the levels of IL-12p70 were
increased by 4-6 times when combined with IFN-α, whereas
no changes in IL-10 levels were observed. Conclusion: It is
well known that IL-10 is an anti-inflammatory cytokine and IL-
12p70 is a cytokine to enhance cytopathic and non-cytopathic
effects on immune cells. Therefore, our results strongly
suggest that immunological favorable effects on HBV-infected
hepatocytes are theoretically expected by monotherapy
of nucleotide analogues (ADV or TDF) or combination with
IFN-α. The mechanisms of nucleotide analogues on inhibitory
effect of IL-10 production are under investigation.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2018-10-23 15:30 |只看该作者
s 458C
阿德福韦或替诺福韦相互增强
LPS刺激的促炎性细胞因子
PBMC通过抑制IL-10的产生
CD14 +单核细胞
Kazumoto Murata,国际大学消化系统
健康与福利;基因组医学科学项目,
马萨亚国家全球健康和医学中心
Sugiyama,基因组医学科学项目,国家中心
全球健康与医学和Masashi Mizokami,
国家全球卫生和医学中心
背景:Nucleos(t)ide类似物(NUC)可以控制
乙型肝炎病毒(HBV)通过抑制其逆转录酶,
但通常需要终生疗法。我们最近
发现阿德福韦(ADV)或替诺福韦(TDF)有
另外的药理学抗HBV作用诱导
胃肠道(GI)中的IFN-13。自肠道
脂多糖(LPS)可以穿过肠道并扩散
进入门静脉,我们假设口服给药
NUC可能影响LPS诱导的细胞因子的产生
外周血单核细胞(PBMC)。方法:
整个PBMC或各种细胞(CD3,CD14,CD19或CD56) -
从健康志愿者(HV)获得的耗尽的PBMC是
与NUC孵育(拉米夫定; LAM,ADV,恩替卡韦; ETV,
TDF)或阴性对照(DMSO),用刺激后
LPS,有或没有IFN-α。慢性乙型肝炎患者的PBMC
HBV感染(无症状携带者(AC); n = 8,慢性
肝炎(CH); n = 10,肝硬化(LC); n = 5)也被使用。
通过Bio-测量上清液中的每种细胞因子水平
Plex细胞因子测定或酶联免疫吸附测定
(ELISA)。在一些实验中,抗体或重组体
白细胞介素(IL)-10,IL-12p70或肿瘤坏死的蛋白质
当刺激PBMC时使用因子(TNF)-α
与NUC。结果:Bio-Plex细胞因子检测显示
ADV或TDF显着诱导IL-12p70和TNF-α,
与DMSO,LAM和ETV相比,抑制IL-10。
在来自所有3的PBMC中类似地观察到这些模式
HV,使用来自其他的PBMC通过ELISA确认
HV。没有其他细胞因子显示出显着性。 ADV或
TDF以剂量依赖性调节这些细胞因子水平
这种方式完全被废除了
CD14 +单核细胞。使用得到的可比结果
来自HBV患者的PBMC尽管所有细胞因子水平均为
与HV,AC相比,LC患者显着降低
或CH。 IL-的单克隆抗体和重组蛋白
10显着增强和抑制IL-12p70或TNF-α,
分别以剂量依赖的方式。相比之下,没有
单克隆抗体或IL-重组蛋白
12p70和TNF-α改变IL-10水平,无论它们如何
使用浓度。总的来说,ADV或TDF最初抑制
LPS介导的IL-10产生和相互诱导的IL-
12p70和TNF-α。此外,IL-12p70的水平是
当与IFN-α组合时,增加4-6倍,而
没有观察到IL-10水平的变化。结论:是的
众所周知,IL-10是一种抗炎细胞因子和IL-
12p70是一种增强细胞病变和非细胞病变的细胞因子
对免疫细胞的影响。因此,我们的结果强烈
提示免疫学对HBV感染有利
理论上,单一疗法可以预期肝细胞
核苷酸类似物(ADV或TDF)或与其组合
IFN-α。核苷酸类似物抑制的机制
IL-10产生的影响正在调查中。
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-6-26 19:13 , Processed in 0.014992 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.